证券之星消息，8月4日医疗美容板块较上一交易日下跌0.9%，*ST美谷领跌。当日上证指数报收于 3583.31，上涨0.66%。深证成指报收于11041.56，上涨0.46%。医疗美容板块个股涨跌见下表： 从资金流向上来看，当日医疗美容板块主力资金净流出5284.74万元，游资资金净流入2440.66万元，散户 资金净流入2844.08万元。医疗美容板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 183.25 | -0.69% | 2.05万 | 3.73 Z | | 832982 | 锦波生物 | 319.85 | -0.95% | 7186.67 | 2.30 Z | | 688363 | 华熙生物 | 51.35 | -1.15% | 2.85万 | 1.46 Z | | 000615 | *ST美谷 | 3.0 ...

Industry Overview - The medical beauty industry in China has developed rapidly despite its late start, with a comprehensive industry chain that includes upstream raw material suppliers and medical equipment providers, midstream public and private institutions, and downstream consumers [1][2]. Key Players - Major upstream raw material manufacturers include Huaxi Biological, Aimeike, Haohai Biological, Huadong Pharmaceutical, and Jiao Dian Biological, while medical equipment is primarily supplied by foreign leading manufacturers [2]. - Midstream medical institutions consist of well-known entities such as Huahan Plastic Surgery, Lido Plastic Surgery, and Ruile Medical, along with emerging platforms like Xinyang and Gem [2]. Regional Distribution - The coastal regions of China have a dense distribution of representative enterprises in the medical beauty industry, with significant concentrations in Beijing, Shanghai, and Guangzhou, which are home to top research institutions and production companies [5]. - These regions attract numerous renowned medical beauty hospitals and clinics, providing comprehensive and high-quality services to consumers [5]. Business Layout of Representative Companies - Companies like Aimeike and Huaxi Biological focus on domestic sales, while others like Langzi and Huahan have diversified regional strategies across various provinces [7]. - Some companies specialize in product development, while others emphasize service delivery, with notable examples including Aimeike and Haohai focusing on product R&D, and Aoyuan Meigu's strong hospital brand image [7]. Financial Performance - Aimeike reported a medical beauty business revenue of 3.023 billion yuan, with a business proportion of 99.90%, indicating a strong focus on medical devices [8]. - Huadong Pharmaceutical generated 2.041 billion yuan from its medical beauty segment, accounting for 4.87% of its total business [9]. Investment Trends and Future Plans - Companies are actively expanding their business layouts with a trend towards diversification and internationalization, such as Aimeike's acquisition of a Korean company and Haohai's collaboration with a U.S. firm for product innovation [10][11]. - Huadong Pharmaceutical is expanding its medical beauty business through acquisitions and partnerships, while Huaxi Biological is investing in new technologies and products [10][11].

证券之星消息，8月1日医疗美容板块较上一交易日上涨0.06%，*ST美谷领涨。当日上证指数报收于 3559.95，下跌0.37%。深证成指报收于10991.32，下跌0.17%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 3.12 | 2.30% | 11.73万 | 3619.67万 | | 688363 | 华熙生物 | 56'15 | 0.25% | 3.01万 | 1.57 Z | | 300896 | 爱美客 | 184.53 | -0.20% | 2.32万 | 4.31亿 | | 832982 | 锦波生物 | 322.91 | -3.46% | 1.04万 | 3.39亿 | 从资金流向上来看，当日医疗美容板块主力资金净流出1180.44万元，游资资金净流入977.47万元，散户 资金净流入202.97万元。医疗美容板块个股资金流向见下表： | 代码 | | | 名称 主力净流入（元） 主力净占比 游资净流入（元 ...

| 代码 | | | 名称 | | | | | --- | --- | --- | --- | --- | --- | --- | | 000615 *ST美谷 | 214.37万 | 7.42% | -53.63万 | -1.86% | -160.74万 | -5.57% | | 688363 华熙生物 | -420.73万 | -2.05% | 659.31万 | 3.22% | -238.58万 | -1.16% | | 300896 爱美客 | -7982.73万 | -13.22% | 2959.66万 | 4.90% | 5023.07万 | 8.32% | | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 3.05 | 1.33% | 9.42万 | 2888.14万 | | 832982 | 锦波生物 | 334.50 | -0.26% | 6835.71 | 2.28亿 | | 688363 | 华熙生物 | 51.82 | -2.04% | 3 ...

证券代码：000615 证券简称：*ST美谷 公告编号：2025-069 奥园美谷科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 奥园美谷科技股份有限公司（以下简称"公司"）于 2025 年 7 月 30 日收到 中国民生银行股份有限公司广州分行（以下简称"民生银行""转让方"）和中 国信达资产管理股份有限公司广东省分公司（以下简称"信达资管" "受让方"） 出具的《债权及担保权利转让暨催收通知》（（2025）民生信达粤 03 号），现 将相关事项公告如下： 单位：元 | 借款人 | 借款合同名称 担保人 奥园集团有限公司、奥园美谷 | 担保合同名称 | 基准日债权余额 | | --- | --- | --- | --- | | 《并购贷款借 | 科技股份有限公司、广州奥美 | 《保证合同》 | | | | 产业投资有限公司、广州奥悦 | 《质押合同》 | | | 广州奥美产业 | 款合同》及相 | | | | | 美产业投资有限公司、广州奥 | 《应收账款质 | 370,153,855.63 | | 投资有限公司 | 应《借款变更 | | ...

证券代码：000615 证券简称：*ST美谷 公告编号：2025-069 奥园美谷科技股份有限公司 关于公司收到债权及担保权利转让暨催收通知的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 奥园美谷科技股份有限公司（以下简称"公司"）于 2025 年 7 月 30 日收到 中国民生银行股份有限公司广州分行（以下简称"民生银行""转让方"）和中 国信达资产管理股份有限公司广东省分公司（以下简称"信达资管""受让方"） 出具的《债权及担保权利转让暨催收通知》（（2025）民生信达粤 03 号），现 将相关事项公告如下： 一、债权及担保权利转让与催收通知的主要内容 根据中国民生银行股份有限公司广州分行与中国信达资产管理股份有限公 司广东省分公司达成的资产转让协议，转让方将其对下文清单所列借款人及其担 保人享有的主债权及借款合同、担保合同等其他相关协议项下的全部权利，依法 转让给受让方。 现转让方及受让方共同以邮寄送达的方式通知各借款人、担保人以及借款人、 担保人因各种原因发生更名、改制、歇业、吊销营业执照或丧失民事主体资格等 情况的相关承债主体或清算主体上述债 ...

证券之星消息，7月30日医疗美容板块较上一交易日上涨0.5%，爱美客领涨。当日上证指数报收于 3615.72，上涨0.17%。深证成指报收于11203.03，下跌0.77%。医疗美容板块个股涨跌见下表： | 代码 | | | 名称 | | | | | --- | --- | --- | --- | --- | --- | --- | | 688363 华熙生物 | 209.44万 | 0.80% | -309.19万 | -1.19% | 99.75万 | 0.38% | | 000615 *ST美谷 | -221.92万 | -10.61% | -76.08万 | -3.64% | 298.00万 | 14.25% | | 300896 爱美客 | -1295.20万 | -1.73% | 3414.81万 | 4.56% | -2119.61万 | -2.83% | 从资金流向上来看，当日医疗美容板块主力资金净流出1307.69万元，游资资金净流入3029.54万元，散户 资金净流出1721.85万元。医疗美容板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104 ...

Group 1 - The medical beauty sector experienced a decline of 0.17% on July 29, with Ai Meike leading the drop [1] - The Shanghai Composite Index closed at 3609.71, up 0.33%, while the Shenzhen Component Index closed at 11289.41, up 0.64% [1] - Major stocks in the medical beauty sector showed mixed performance, with Jinbo Biological up 1.82% and Ai Meike down 0.73% [1] Group 2 - The medical beauty sector saw a net outflow of 37.97 million yuan from main funds, while retail investors contributed a net inflow of 56.99 million yuan [1] - Specific stock performances included Huaxi Biological with a net outflow of 1.47 million yuan and *ST Meigu with a net inflow of 0.55 million yuan [2]

Group 1 - The medical beauty market in China is experiencing continuous growth, with the number of compliant specialized medical beauty institutions reaching 19,880 in the first half of 2024, an increase of 1,296 institutions or 7% from January 2024 [1][3] - The increase in compliant medical beauty institutions is driven by enhanced regulatory oversight and a growing consumer demand for legitimate medical beauty services [1][3] Group 2 - There is a significant shortage of compliant medical beauty doctors, with an estimated gap of around 20,000 qualified professionals, while the total number of medical beauty practitioners is approximately 1.02 million [4] - The annual growth rate of medical beauty practitioners is around 10%, but the supply of qualified professionals is only increasing at a rate of 5%-8%, highlighting a supply-demand imbalance [4] Group 3 - The distribution of medical beauty positions in China shows a clear imbalance, with only 10% of positions being medical technical roles, which require solid medical knowledge and qualifications [6] - Over 60% of positions are in marketing and operations, which are crucial for attracting customers and driving business growth, but this focus may compromise the quality of medical services [6] Group 4 - The educational requirements for core positions in the medical beauty industry are increasing, with a trend towards higher educational qualifications among professionals [9] - Large medical beauty companies are setting stricter educational standards, with some requiring a full-time bachelor's degree for medical technical roles [9] Group 5 - The distribution of medical beauty talent in China shows a pattern of concentration in eastern regions and high-tier cities, with first-tier cities holding over 50% of medical beauty positions [10] - New first-tier cities are competing for mid-level talent through differentiated strategies, while lower-tier cities struggle due to a lack of local training capabilities [10]

证券代码：000615 证券简称：*ST美谷 公告编号：2025-068 奥园美谷科技股份有限公司 关于重大仲裁事项进展暨收到《执行通知书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次案件所处的诉讼（仲裁）阶段：执行； 2、上市公司所处的当事人地位：被申请人； 3、涉案的金额：135,306,299.04 元（不含仲裁费）； 4、对上市公司损益产生的影响：公司将根据企业会计准则的相关规定和诉 讼案件等情况进行财务处理，具体处理结果以及对公司本期期末业绩的影响，以 会计师事务所最终年度审计结果为准。 敬请广大投资者注意投资风险。 一、定向融资计划仲裁案的基本情况 京汉控股集团有限公司（以下简称"京汉控股""申请人"）因定向融资计 划向北京仲裁委员会申请仲裁，仲裁请求为：请求裁决被申请人一京汉置业集团 有限责任公司（以下简称"京汉置业"）向申请人支付"京汉置业 2021 年定向 融资计划三期"产品剩余本金人民币 8,820 万元；裁决被申请人一向申请人支付 逾期支付"京汉置业 2021 年定向融资计划三期"产品剩余本金的违约金（以应 ...